Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
By restoring glucose-regulated insulin secretion, glucagon-like peptide-1-based (GLP-1-based) therapies are becoming increasingly important in diabetes care. Normally, the incretins GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) jointly maintain normal blood glucose levels by stimulation of insulin secretion in pancreatic β cells. However, the reason why only GLP-1-based drugs are effective in improving insulin secretion after presentation of diabetes has not been resolved. ATP-sensitive K+ (KATP) channels play a crucial role in coupling the systemic metabolic status to β cell electrical activity for insulin secretion. Here, we have shown that persistent membrane depolarization of β cells due to genetic (β cell-specific Kcnj11-/- mice) or pharmacological (long-term exposure to sulfonylureas) inhibition of the KATP channel led to a switch from Gs to Gq in a major amplifying pathway of insulin secretion. The switch determined the relative insulinotropic effectiveness of GLP-1 and GIP, as GLP-1 can activate both Gq and Gs, while GIP only activates Gs. The findings were corroborated in other models of persistent depolarization: a spontaneous diabetic KK-Ay mouse and nondiabetic human and mouse β cells of pancreatic islets chronically treated with high glucose. Thus, a Gs/Gq signaling switch in β cells exposed to chronic hyperglycemia underlies the differential insulinotropic potential of incretins in diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 14×
“However, downregulation of the GLP-1 receptor (GLP-1R) has also been reported in T2D, yet GLP-1 retains its insulinotropic potential (21, 23). β cell KATP channels comprise 2 subunits: the pore-forming subunit Kir6.”
BackgroundInfluentialBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Regulation of insulin release by calcium.
Wollheim, C. B., & Sharp, G. W. (1981) · Physiological Reviews · doi:10.1152/physrev.1981.61.4.914 · Cited by 849
Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793 · cited 1×
“KATP channels in β cells transduce changes in blood glucose, via acceleration of glucose metabolism, into electrical activity required for the release of insulin (1, 5).”
BackgroundSelf-citationMetabolic Signaling in Fuel-Induced Insulin Secretion
Prentki, M., Matschinsky, F. M., & Madiraju, S. R. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.018 · Cited by 548 · cited 1×
“Of these factors, glucose is the primary initiator of insulin secretion (1, 2).”
BackgroundNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 14×
“However, downregulation of the GLP-1 receptor (GLP-1R) has also been reported in T2D, yet GLP-1 retains its insulinotropic potential (21, 23). β cell KATP channels comprise 2 subunits: the pore-forming subunit Kir6.”
BackgroundInfluentialVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430 · cited 2×
“The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.”
BackgroundBraun, M., Ramracheya, R., Bengtsson, M., Zhang, Q., Karanauskaite, J., Partridge, C., Johnson, P. R., & Rorsman, P. (2008) · Diabetes · doi:10.2337/db07-0991 · Cited by 417
Self-citation
Cited by
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“Most recently, GLP-1R has been shown to signal predominantly via Gqα in mouse and human β-cells subject to chronic depolarizing stimuli (KATP channel mutations, hyperglycemia) (65).”
BackgroundMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“receptors, it remains unclear why GIPR signalling is defective in type 2 diabetes; the lack of GIP responsivity has been ascribed to hyperglycaemia-associated switching of G protein signalling in beta cells [48].”
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“reas, pancreatic beta cells are chronically depolarised, which in turn leads to a switch from Gas to Gaq as the major pathway for stimulating insulin secretion [64].”
BackgroundInfluentialG Protein-Coupled Receptors: A Century of Research and Discovery
Liu, S., Anderson, P. J., Rajagopal, S., Lefkowitz, R. J., & Rockman, H. A. (2024) · Circulation Research · doi:10.1161/circresaha.124.323067 · Cited by 176
“165,166 At the moment, the question of what specific properties will result in the development of better beta-blockers is still under investigation, though research in our laboratories has focused on evaluating and enhancing the effects of β -arrestin- biased signaling of beta-blockers.”
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“A switch of Gαs and Gαq pathways has been found under certain conditions, including persistent depolarization of cell membrane [30], and reduction in GLP-1 concentration to picomolar [41].”
BackgroundGLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
“Similarly, chronic beta cell depolarization via either elevated glucose or K ATP -channel inactivating mutations, leads to a switch from G α s to G α q signaling [71].”
Metadata
- Authors
- Oduori, O. S., Murao, N., Shimomura, K., Takahashi, H., Zhang, Q., Dou, H., Sakai, S., Minami, K., Chanclon, B., Guida, C., Kothegala, L., Tolö, J., Maejima, Y., Yokoi, N., Minami, Y., Miki, T., Rorsman, P., & Seino, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-11-16
- Volume
- 130
- Issue
- 12
- Pages
- 6639-6655
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3099310113
- Cited by
- 106
- References
- 20
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.